An important observation from the work by Traxl and colleagues, which may have important clinical significance for the use of [11C]erlotinib, is the fact that the distribution of [11C]erlotinib in peripheral, and probably tumor tissues, was affected by ABCB1/ABCG2. The gene discussed is ABCG2; the disease is neoplasm.